Events

Events

Upcoming Events
Past Events
Biogen at the UBS Global Healthcare Conference (replay)
May 21, 2018
Biogen at the Cowen and Company 38th Annual Health Care Conference (replay)
Mar 12, 2018
Biogen at the Leerink Partners 7th Annual Global Healthcare Conference (replay)
Feb 14, 2018
Biogen at the 36th Annual J.P. Morgan Healthcare Conference Q & A Session (replay)
Jan 8, 2018
Biogen at the Guggenheim 5th Annual Healthcare Conference (replay)
Dec 13, 2017
Biogen at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference (replay)
Nov 29, 2017
Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (replay)
Nov 4, 2017
Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (replay)
Nov 2, 2017
Biogen at the Morgan Stanley Global Healthcare Conference (replay)
Sep 11, 2017
Biogen at the Bernstein 33rd Annual Strategic Decisions Conference (replay)
May 31, 2017

Cautionary Statement and Acknowledgment

By proceeding further, you acknowledge and agree that your access to information contained in the “Medical and Scientific Conferences Presentations” section of the Biogen website:

  • Is provided for informational purposes for use by the investor community only; and
  • May include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective..

In addition, the scientific or medical presentations included in the “Medical and Scientific Conferences Presentations” section of the Biogen website may contain forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including those risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission (SEC) available at the SEC’s Internet (www.sec.gov). You should not place undue reliance on these statements or the scientific data presented. Forward-looking statements speak only as of the date of each presentation. Except as required by law, Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.